Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: A prospective cohort study

Lupus

Volumn 14, Issue 2, 2005, Pages 120-128

  Ruffatti, Amelia ^a,b   Favaro, M ^a   Tonello, M ^a   De Silvestro, G ^b   Pengo, V ^a   Fais, G ^a   Suma, V ^b   Chiarelli, S ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Low molecular weight heparin; Nadroparin; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; CALCIUM; CENTROMERE ANTIBODY; DNA ANTIBODY; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; NADROPARIN; PHOSPHOLIPID ANTIBODY; RO ANTIBODY; SELEPARINA; SM ANTIBODY; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE HEPATITIS; BEHCET DISEASE; BIRTH WEIGHT; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; COOMBS TEST; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETUS WASTAGE; GRAVES DISEASE; HASHIMOTO DISEASE; HELLP SYNDROME; HEP 2 CELL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; LOW DRUG DOSE; PATIENT COMPLIANCE; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; SOLUTIO PLACENTAE; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; NADROPARIN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 14744268678     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2071oa     Document Type: Article

References (41)

1. Tincani A, Branch W, Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-529.
2. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135-144.
3. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstet Gynecol 2003; 101: 1333-1344.
4. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-136.
5. Stone S, Hunt BJ, Seed PT, Parmar K, Khamashta MA, Poston L. Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and healthy pregnancy. Am J Obstet Gynecol 2003; 188: 454-460.
6. Ensom MH, Stephenson MD. Low-molecular-weight heparins in pregnancy. Pharmacotherapy 1999; 19: 1013-1025.
7. Sanson BJ, Lensing AWA, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-672.
8. Makatsaria AD, Bitsadze VO, Dolgushina NV. Use of the low-molecular-weight heparin nadroparin during pregnancy. A review. Curr Med Res Opin 2003; 19: 4-12.
9. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular-weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999; 14: 489-495.
10. Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995; 33: 14-20.
11. Franklin RD, Kutteh WH. Effects of unfractionated and low-molecular-weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 2003; 101: 455-462.
12. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.
13. Chigot P, DE Gennes C, Samama MM. Effects of unfragmented and low weight heparin and the induction of osteoporosis. J Mal Vasc 1996; 21. 121-125.
14. Tincani A, Balestrieri G, Allegri F et al. Overview on anticardiolipin ELISA standardization. J Autoimmun 2000; 15: 195-197.
15. Brandt JT, Triplett DA, Alving B, Scarrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemostasis 1995; 74: 1185-1190.
16. Galton M, Merritt K, Beller FK. Coagulation studies on the peripheral circulation of patients with toxaemia of pregnancy: a study for the evaluation of disseminated extravascular coagulation and toxaemia. J Reprod Med 1971; 6: 89-100.
17. Redman CWG, Bonnar J, Beilin L. Early platelet consumption in pre-eclampsia. Br Med J 1978; 1: 467-469.
18. Lindheimer MD, Katz AI. Pathophysiology of pre-eclampsia. Ann Rev Med 1981; 32: 273-289.
19. Romero R, Mazor M, Lockwood CJ. Clinical significance, prevalence and natural history of thrombocytopenia in pregnancy-induced hypertension. Am J Perinatal 1989; 6: 32-38.
20. Shiach CR. Monitoring of low molecular weight heparin in pregnancy. Hematol 2003; 8: 47-52.
21. Sephton V, Farquharson RG, Topping J et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101: 1307-1311.
22. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062-1068.
23. Blombäck M, Bremme K, Hellgren M, Siegbahn A, Lindbeg H. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy-a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9: 1-9.
24. Melissari E, Parker C, Wilson NV et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-656.
25. Boda Z, Laszlo P, Rejtõ et al. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Thromb Haemost 1996; 76: 128.
26. Hunt BJ, Doudhty HA, Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
27. Casele HL, Laiefer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113-1117.
28. Pettila V, Kaaja R, Leinonen P, Ekblad P, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (Dalteparin) in pregnancy. Thromb Res 1999; 96: 275-282.
29. Bonnar J, Green R, Norris L. Perinatal aspects of inherited thrombophilia. Semin Thromb Haemost 1999; 25: 481-485.
30. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
31. Fiehn C. Treatment of woman with aPL in pregnancy. Ann Rheum Dis 2001; 60: 717-718 (letter).
32. Ruffatti A, Chiarelli S, Favaro M et al. Could placental abruption be an antiphospholipid related disorder? Clin Exp Rheumatol 2004; 22: 380-381 (letter).
33. Asherson RA, Piette JC, Cervera R. 'Primary', 'Secondary', 'Seronegative', 'Catastrophic' and other subsets of the Antiphospholipid Syndrome. In Asherson RA, Cervera R, Piette JC, Shoenfeld Yed. The Antiphospholipid Syndrome II. Elsevier Science: Amsterdam, 2002: 285-296.
34. Ruffatti A, De Silvestro G, Ghirardello A et al. A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation. J Intern Med 1994; 235: 81-83.
35. Watson WJ, Katz VL, Bowes WA Jr. Plasmapheresis during pregnancy. Obstet Gynecol 1990; 76: 451-457.
36. Rock JA, Shirey RS, Braine HG, Ness PM, Kickler TS, Niebyl JR. Plasmapheresis for the treatment of repeated early pregnancy wastage associated with anti-P. Obstet Gynecol 1985; 66: 57S-60S.
37. Huong TLD, Wechsler B, Bletry O, Vauthier-Brouzes D, Lefebvre G, Piette J-C. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 2001; 28: 2025-2030.
38. Rosove MH, Tabsh K, Wasserstrum N, Howard P, Hahn BH, Kalunian K. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antobodies. Obstet Gynecol 1990; 75: 630-634.
39. Ruffatti A, Orsini A, Di Lenardo L et al. A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss. Clin Exp Rheumatol 1997; 15: 499-505.
40. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
41. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-257.